Evidence map›Paper›PMID 38988713›Full record

ArticleFrontiers in oncology2024

Wenwen Zhang, Shanhu Hao, Zhiguo Wang, Tingting Ding, Guoxu Zhang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Efficacy and safety of anlotinib combined withFrontiers in endocrinology · 2025
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenwen ZhangCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China.
Shanhu HaoDepartment of Nuclear Medicine, General Hospital of the Northern Theater Command, Shenyang, China.
Zhiguo WangCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China.
Tingting DingDepartment of Nuclear Medicine, General Hospital of the Northern Theater Command, Shenyang, China.
Guoxu ZhangCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the feasibility and evaluate the safety and effectiveness of Computed Tomography (CT) guided Methods: A retrospective analysis was conducted on 42 patients with RAIR-DTC and lymph node metastases who were admitted to the General Hospital of the Northern Theater Command between December 2016 and January 2019. During this analysis, physicians utilized preoperative CT images to design an intraoperative plan using TPS. The dosimetric parameters of the postoperative plan were then compared to the preoperative plan. Additionally, this study examined the changes in tumor size and tumor-related marker Thyroglobulin (Tg) values in patients at 2, 6, and 12 months after the operation. Results: The number of Conclusion: Referring to the TPS preoperative plan, the

Indexed as

brachytherapyiodine radioisotopelymph nodesradiation dosethyroid tumortumor metastasis

Identifiers

PMID38988713
PMCPMC11233436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.